Computational methods in internal radiation dosimetry

Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine

Volumn , Issue , 2002, Pages 84-107

  Zanzonico, Pat B ^a   Poston, John W ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Texas AandM University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35448955912     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (84)

1. Fisher D R 1994 Radiation dosimetry for radioimmunotherapy. An overview of current capabilities and limitations Cancer 73 905-11
2. Howell RW, Wessels BW, Loevinger R, Watson E E, BolchWE, Brill A B, Charkes N D, Fisher D R, Hays M T, Robertson J S, Siegel J A and Thomas S R 1999 The MIRD perspective 1999. Medical Internal Radiation Dose Committee J. Nucl. Med. 40 3S-10S
3. Stabin M, Tagesson M, Thomas S R, Ljungberg M and Strand S E 1999 Radiation dosimetry in nuclear medicine Appl. Radiat. Isot. 50 73-87
4. Zanzonico P B 2000 Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments J. Nucl. Med. 41 297-308
5. Rossi H 1968 Microscopic energy distributions in irradiated manner. In Radiation Dosimetry, vol I: Fundamentals eds F Attix, W Roesch and E Tochlin (New York: Academic) pp 43-92
6. ICRU 1980 Radiation Quantities and Units. International Commission on Radiation Units and Measurements (ICRU) Report 33. International Commission on Radiation Units and Measurements (ICRU), Bethesda, MD
7. ICRU 1983 Microdosimetry. International Commission on Radiation Units and Measurements (ICRU) Report 36. International Commission on Radiation Units and Measurements (ICRU), Bethesda, MD
8. NCRP 1985 SI Units in Radiation Protection and Measurements. National Council on Radiation Protection and Measurements (NCRP) Report 82. National Council on Radiation Protection and Measurements (NCRP), Bethesda, MD
9. BEIR 1990 Health Effects of Exposure to Low Levels of Ionizing Radiation (BEIR V). Biological Effects of Ionizing Radiation (BEIR) Committee, National Research Council. National Academy Press, Washington, DC
10. ICRP 1990 1990 Recommendations of the International Commission on Radiological Protection. International Commission on Radiological Protection (ICRP) Publication 60, Annals of the ICRP 21 (Elmsford, NY: Pergamon)
11. Johns H and Cunningham J 1974 The Physics of Radiology (Springfield: Thomas)
12. Attix F 1986 Introduction to Radiological Physics and Radiation Dosimetry (New York: Wiley)
13. Loevinger R, Budinger T, Watson E, Atkins H, Blau M, Lathrop K, Poston J, Robertson J, Thomas S and Weber D 1991 MIRD Primer for Absorbed Dose Calculations (revised edition) (New York: Society of Nuclear Medicine)
14. Snyder W, Ford M, Warner G and Fisher H Jr 1969 Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet No 5 J. Nucl. Med. 10 (Suppl. 3) 5-52
15. Snyder W, Ford M, Warner G and Watson S 1975 ‘S’, Absorbed dose per unit cumulated activity for selected radionuclides and organs. Medical Internal Radiation Dose (MIRD) Pamphlet No 11 (New York: Society of Nuclear Medicine)
16. Zanzonico P, Brill A and Becker D 1995 Radiation dosimetry. In Principles of Nuclear Medicine eds H Wagner, Z Szabo and J Buchanan (Philadelphia: Saunders) 2nd edition pp 106-34
17. ICRP 1988 Radiation Dose to Patients from Radiopharmaceuticals. International Commission on Radiological Protection (ICRP) Publication 53 (New York: Pergamon)
18. Watson E 1999 Foreword J. Nucl. Med. 40 1S-2S
19. Loevinger R 1989 The MIRD perspective. In Dosimetry of Administered Radionuclides eds S Adelstein, A Kassis and R Burt (Washington, DC: American College of Nuclear Physicians/Department of Energy) pp 29-43
20. Cristy M and Eckerman K 1987 Specific Absorbed Fractions of Energy at Various Ages from Internal Photon Sources (Parts I-VII). Oak Ridge National Laboratory Report ORNL/TM-8381/V1-7 (Springfield, VA: National Technical Information Service, Dept of Commerce)
21. ICRP 1975 Report of the Task Group on Reference Man ICRP Publication 23 (Oxford: Pergamon)
22. Stabin M 1996 MIRDOSE: personal computer software for internal dose assessment in nuclear medicine J. Nucl. Med. 37 538-46
23. Sgouros G, Bigler R and Zanzonico P 1988 DOSCAL: a tumor-incorporating mean absorbed dose calculation program (Abstract) J. Nucl. Med. 29 874
24. Johnson T 1988 MABDOS: a generalized program for internal dosimetry Comput. Meth. Programs Biomed. 37 159-67
25. Johnson T K, McClure D and McCourt S 1999 MABDOSE. II: Validation of a general purpose dose estimation code [In Process Citation] Med. Phys. 26 1396-403
26. Johnson T K, McClure D and McCourt S 1999 MABDOSE. I: Characterization of a general purpose dose estimation code [In Process Citation] Med. Phys. 26 1389-95
27. Weber D, Eckerman K, Dillman L and Ryman J 1989 MIRD: Radionuclide Data and Decay Schemes (New York: Society of Nuclear Medicine)
28. Beierwaltes W H, Nishiyama R H, Thompson N W, Copp J E and Kubo A 1982 Survival time and ‘cure’ in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy J. Nucl. Med. 23 561-8
29. Benua R, Cicale N and Sonenberg M 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer Am. J. Roentgenol. 87 171-82
30. Furhang E E, Larson S M, Buranapong P and Humm J L 1999 Thyroid cancer dosimetry using clearance fitting J. Nucl. Med. 40 131-6
31. Marinelli L, Quimby E and Hine G 1948 Dosage determination with radioactive isotopes. II. Practical considerations in therapy and protection Am. J. Roentgenol. Radium Therapy 59 260-80
32. Marinelli L, Quimby E and Hine G 1948 Dosage determination with radioactive isotopes. I. Fundamental dosage formulae Nucleonics 2 56-66
33. Marinelli L, Quimby E and Hine G 1948 Dosage determination with radioactive isotopes. II. Biological considerations and practical applications Nucleonics 2 44-9
34. Loevinger R, Holt J G and Hine G J 1956 Internal administered radioisotopes. In Radiation Dosimetry eds G J Hine and G L Brownell (New York: Academic) pp 801-73
35. Zanzonico P B 2001 Radiation dosimetry of rhenium-188 Lipiodol: a workshop. In Lecture Notes: Regional Training Workshop on Radionuclide Treatment of Liver Cancer. NMS/11/RTC-2001-01/RCA-1 (Perth) (Perth: International Atomic Energy Agency (IAEA)) pp 128-61
36. Erdi A K, Wessels BW, DeJager R, Erdi Y E, Atkins F B, Yorke E D, Smith L, Huang E, Smiddy M, Murray J et al. 1994 Tumor activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88 human monoclonal antibody Cancer 73 932-44
37. Erdi A K, Yorke E D, LoewMH, Erdi Y E, SarfarazMand Wessels BW 1998 Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy Med. Phys. 25 2226-33
38. Erdi A K, Erdi Y E, Yorke E D and Wessels BW 1996 Treatment planning for radioimmunotherapy Phys. Med. Biol. 41 2009-26
39. Furhang E E, Chui C S and Sgouros G 1996 A Monte Carlo approach to patientspecific dosimetry Med. Phys. 23 1523-9
40. Furhang E E, Chui C S, Kolbert K S, Larson S M and Sgouros G 1997 Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy Med. Phys. 24 1163-72
41. Giap H B, Macey D J, Bayouth J E and Boyer A L 1995 Validation of a dosepoint kernel convolution technique for internal dosimetry Phys. Med. Biol. 40 365-81
42. Giap H B, Macey D J and Podoloff D A 1995 Development of a SPECT-based threedimensional treatment planning system for radioimmunotherapy J. Nucl. Med. 36 1885-94
43. Howell RW, Rao D V and Sastry K S 1989 Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors Med. Phys. 16 66-74
44. Humm J L 1986 Dosimetric aspects of radiolabeled antibodies for tumor therapy J. Nucl. Med. 27 1490-7
45. Humm J L and Cobb L M 1990 Nonuniformity of tumor dose in radioimmunotherapy [see comments] J. Nucl. Med. 31 75-83
46. Koral K F, Zasadny K R, Kessler M L, Luo J Q, Buchbinder S F, Kaminski M S, Francis I and Wahl R L 1994 CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients J. Nucl. Med. 35 1714-20
47. Koral K F, Lin S, Fessler J A, KaminskiM S and Wahl R L 1997 Preliminary results from intensity-based CT-SPECT fusion in I-131 anti-B1 monoclonal-antibody therapy of lymphoma Cancer 80 2538-44
48. Leichner P K and Kwok C S 1993 Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles Med. Phys. 20 529-34
49. Liu A, Williams L, Wong J and Raubitschek A 1997 A voxel source kernel (VSK) method for rapid, patient-specific dose estimates in radioimmunotherapy (RIT) (Abstract) J. Nucl. Med. 38(suppl) 106P
50. Liu A, Williams L E, Lopatin G, Yamauchi D M, Wong J Y and Raubitschek A A 1999 A radionuclide therapy treatment planning and dose estimation system J. Nucl. Med. 40 1151-3
51. Ljungberg Mand Strand S E 1988 Dose planning with SPECT Int. J. Cancer Suppl. 2 67-70
52. Mayer R, Dillehay L E, Shao Y, Song S, Zhang Y G, Bartholomew R M and Williams J R 1994 A new method for determining dose rate distribution from radioimmunotherapy using radiochromic media Int. J. Radiat. Oncol. Biol. Phys. 28 505-13
53. Sgouros G, Barest G, Thekkumthala J, Chui C, Mohan R, Bigler R E and Zanzonico P B 1990 Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides J. Nucl. Med. 31 1884-91
54. Sgouros G, Chiu S, Pentlow K S, Brewster L J, Kalaigian H, Baldwin B, Daghighian F, Graham M C, Larson S M and Mohan R 1993 Three-dimensional dosimetry for radioimmunotherapy treatment planning J. Nucl. Med. 34 1595-601
55. Sgouros G 1999 Treatment planning for internal emitter therapy: methods, applications and clinical implications. In Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium (ORISE 99-0164) eds A Schlafke-Stelson, M Stabin and R Sparks (Oak Ridge, TN: US Dept of Energy and Oak Ridge Associated Universities) pp 13-25
56. Kolbert K S, Sgouros G, Scott A M, Bronstein J E, Malane R A, Zhang J, Kalaigian H, McNamara S, Schwartz L and Larson S M 1997 Implementation and evaluation of patient-specific three-dimensional internal dosimetry J. Nucl. Med. 38 301-8
57. Uchida I, Yamada Y, Oyamada H and Nomura E 1992 Calculation algorithm of three-dimensional absorbed dose distribution due to in vivo administration of nuclides for radiotherapy Kaku Igaku 29 1299-306
58. Wessels B W, Yorke E D and Bradley E W 1990 Dosimetry of heterogeneous uptake of radiolabeled antibody for radioimmunotherapy Front. Radiat. Ther. Oncol. 24 104-8
59. Akabani G, Hawkins W, EckbladeMand Leichner P 1997 Patient-specific dosimetry using quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution J. Nucl. Med. 38 308-14
60. BolchW E, Bouchet L G, Robertson J S, Wessels BW, Siegel J A, Howell R W, Erdi AK, Aydogan B, Costes S, Watson E E, Brill A B, Charkes ND, FisherD R, HaysM T and Thomas SR 1999 MIRD Pamphlet No 17: The dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee J. Nucl. Med. 40 11S-36S
61. Adelstein S, Kassis A and Sastry K 1986 Cellular vs organ approaches to dose estimates. In Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium (Conf-85113 (DE86010102) eds A Schlafke-Stelson and E Watson (Oak Ridge, TN: USDept of Energy and Oak Ridge Associated Universities) pp 13-25
62. Goddu S M, Rao D V and Howell R W 1994 Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides J. Nucl. Med. 35 521-30
63. Goddu S, Howell R, Bouchet L, Bolch W, Rao D, Budinger T, Fisher D, Hays M, Lathrop K, Robertson J, Siegel J, Thomas S, Watson E and Wessels B 1997 MIRD Cellular S Factors: Self-Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Monoenergetic Electrons and Alpha Particle Emitters Incorporated into Different Cell Compartments (Reston, VA: Society of Nuclear Medicine)
64. Griffiths G L, Govindan S V, Sgouros G, Ong G L, Goldenberg DMand MattesMJ 1999 Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies Int. J. Cancer 81 985-92
65. Humm J L, Howell R W and Rao D V 1994 Dosimetry of Auger-electron-emitting radionuclides: Report No 3 of AAPM Nuclear Medicine Task Group No 6 Med. Phys. 21 1901-15 [published erratum appears in Med. Phys. 1995 22 1837]
66. Humm J L, Macklis RM, Lu X Q, Yang Y, Bump K, Beresford B and Chin LM 1995 The spatial accuracy of cellular dose estimates obtained from 3D reconstructed serial tissue autoradiographs Phys. Med. Biol. 40 163-80
67. Humm J 1987 A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy Int. J. Radiat. Oncol. Biol. Phys. 13 1767-73
68. Macklis R M, Lin J Y, Beresford B, Atcher R W, Hines J J and Humm J L 1992 Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis Radiat. Res. 130 220-6
69. O’Donoghue J A and Wheldon T E 1996 Targeted radiotherapy using Auger electron emitters Phys. Med. Biol. 41 1973-92
70. WrennME, Howells GP, Hairr LMand Paschoa A S 1973 Auger electron dosimetry Health Phys. 24 645-53
71. Yorke E D, Williams L E, Demidecki A J, Heidorn D B, Roberson P L and Wessels B W 1993 Multicellular dosimetry for beta-emitting radionuclides: autoradiography, thermoluminescent dosimetry and three-dimensional dose calculations Med. Phys. 20 543-50
72. Zalutsky M R, Stabin M, Larsen R H and Bigner D D 1997 Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate Nucl. Med. Biol. 24 255-61
73. Kassis A I, Adelstein S J, Haydock C and Sastry K S 1980 Radiotoxicity of 75Se and 35S: theory and application to a cellular model Radiat. Res. 84 407-25
74. Kassis A I, Adelstein S J, Haydock C, Sastry K S, McElvany K D and Welch M J 1982 Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells Radiat. Res. 90 362-73
75. Kassis A I, Adelstein S J, Haydock C and Sastry K S 1983 Thallium-201: an experimental and a theoretical radiobiological approach to dosimetry J. Nucl. Med. 24 1164-75
76. Kassis A I, Sastry K S and Adelstein S J 1985 Intracellular distribution and radiotoxicity of chromium-51 in mammalian cells: Auger-electron dosimetry J. Nucl. Med. 26 59-67
77. 125I in mammalian cells Radiat. Res. 111 305-18
78. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes Radiat. Res. 109 78-89
79. Kassis A I 1992 The MIRD approach: remembering the limitations J. Nucl. Med. 33 781-2 [editorial; comment]
80. Tagesson M, Ljungberg M and Strand S E 1996 A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system Acta Oncol. 35 367-72
81. O’Donoghue J A 1999 Implications of nonuniform tumor doses for radioimmunotherapy [In Process Citation] J. Nucl. Med. 40 1337-41
82. Scott A M, Macapinlac H A, Divgi C R, Zhang J J, Kalaigian H, Pentlow K, Hilton S, Graham M C, Sgouros G, Pelizzari C et al 1994 Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma J. Nucl. Med. 35 1976-84
83. Scott AM, Macapinlac H, Zhang J J, Kalaigian H, GrahamMC, Divgi C R, Sgouros G, Goldsmith S J and Larson S M 1994 Clinical applications of fusion imaging in oncology Nucl. Med. Biol. 21 775-84
84. Scott A M, Macapinlac H, Zhang J, Daghighian F, Montemayor N, Kalaigian H, Sgouros G, Graham M C, Kolbert K, Yeh S D et al 1995 Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer J. Nucl. Med. 36 100-3